{"schema_version":"secwatch.filing_event.v1","accession":"0001411685-25-000011","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.558630+00:00","generated_at":"2026-05-27T02:30:11.155532+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vistagen receives US patent for AV-101 to treat neuropathic pain; patent exp. 2034","bullets":["USPTO granted patent for oral non-opioid AV-101 covering neuropathic pain, expiring at least 2034.","Patent strengthens IP for AV-101 targeting disorders involving NMDA receptor, including pain and dyskinesias.","Preclinical data showed AV-101 similar efficacy to gabapentin/pregabalin with better side effect profile.","Phase 1 data in Journal of Pain indicated AV-101 well tolerated; allodynia/hyperalgesia reductions observed.","Vistagen plans to seek strategic partnerships for AV-101 development and commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001411685-25-000011","json":"https://secwatch.observer/filing/0001411685-25-000011.json","markdown":"https://secwatch.observer/filing/0001411685-25-000011.md","text":"https://secwatch.observer/filing/0001411685-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000011/0001411685-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000011/vtgn-20250205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:30:11.155532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}